EJLAL ABU-EL-RUB^1,2,*, RAMADA R. KHASAWNEH¹, FATIMAH A. ALMAHASNEH¹, HANA M. ZEGALLAI^3,4

BIOCELL, Vol.46, No.4, pp. 907-911, 2022, DOI:10.32604/biocell.2022.018306

Abstract The paracrine and immunomodulatory cytokines secreted by mesenchymal stem cells (MSCs), generally referred to as the MSCs derived secretome, has substantial potential for the treatment of many chronic and degenerative diseases. MSCs secretome contains both common and disease specific cytokines and modulators that can be beneficial against a wide range of chronic diseases. Herein, we discuss the MSCs secretome composition profile and its translational applicability and the challenges surrounding its use in clinical settings. More >

FERENC SIPOS^*, GYÖRGYI MŰZES

BIOCELL, Vol.46, No.4, pp. 903-906, 2022, DOI:10.32604/biocell.2022.018200

Abstract Though mesenchymal stem cells (MSCs) are considered as an important pillar of regenerative medicine, their regenerative potential has been shown to be limited in several pathological conditions. The adverse properties of MSC-based cell therapy have drawn attention to the therapeutic use of MSC-derived secretome. However, MSC-originated exosomes and microvesicles can also possess a significant impact on disease development, including cancer. By interchanging secretome, MSCs can interact with tumor cells and promote mutual exchange/induction of cellular markers. In addition, enzymes secreted into and activated within exosomes can result in the acquisition of new tumor cell properties. Therefore, therapeutic applications of MSC-derived… More >